GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $4,451,206.62 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,551 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $95.62, for a total value of $4,451,206.62. Following the completion of the sale, the chief executive officer now directly owns 48,314 shares of the company’s stock, valued at $4,619,784.68. The trade was a 49.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The shares were sold at an average price of $89.44, for a total transaction of $96,416.32.
• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Performance

Shares of WGS opened at $92.20 on Monday. The company has a market capitalization of $2.59 billion, a PE ratio of -47.04 and a beta of 1.91. GeneDx Holdings Corp. has a 52-week low of $8.53 and a 52-week high of $115.60. The company has a 50-day simple moving average of $87.28 and a 200-day simple moving average of $74.48. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. Equities research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in WGS. Charles Schwab Investment Management Inc. boosted its position in shares of GeneDx by 304.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after buying an additional 110,666 shares in the last quarter. FMR LLC lifted its holdings in shares of GeneDx by 295.6% in the third quarter. FMR LLC now owns 53,825 shares of the company’s stock valued at $2,284,000 after purchasing an additional 40,219 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of GeneDx in the third quarter valued at approximately $7,533,000. MetLife Investment Management LLC purchased a new position in shares of GeneDx during the 3rd quarter worth approximately $310,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of GeneDx during the 3rd quarter worth approximately $325,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on WGS. The Goldman Sachs Group lifted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.